178 related articles for article (PubMed ID: 38129137)
1. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract][Full Text] [Related]
2. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
3. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
5. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
[TBL] [Abstract][Full Text] [Related]
6. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
Bai X; Han G; Liu Y; Jiang H; He Q
Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
[TBL] [Abstract][Full Text] [Related]
7. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
Zhou Y; Yamamoto Y; Takeshita F; Yamamoto T; Xiao Z; Ochiya T
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467725
[TBL] [Abstract][Full Text] [Related]
8. Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.
Hu Z; Chen G; Zhao Y; Gao H; Li L; Yin Y; Jiang J; Wang L; Mang Y; Gao Y; Zhang S; Ran J; Li L
Mol Cancer; 2023 Mar; 22(1):55. PubMed ID: 36932387
[TBL] [Abstract][Full Text] [Related]
9. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
10. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
11. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p.
Xing L; Tang X; Wu K; Huang X; Yi Y; Huan J
Aging (Albany NY); 2020 Dec; 13(1):424-436. PubMed ID: 33290256
[TBL] [Abstract][Full Text] [Related]
12. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
[TBL] [Abstract][Full Text] [Related]
13. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
15. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
18. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
19. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
Yang F; Lin L; Li X; Wen R; Zhang X
Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
Sun S; Zhou W; Li X; Peng F; Yan M; Zhan Y; An F; Li X; Liu Y; Liu Q; Piao H
Cancer Commun (Lond); 2021 Sep; 41(9):851-866. PubMed ID: 34251762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
